Department: DRUG CHALLENGE
Can you identify these combination cardiovascular drugs? To find out, match each brand name in Section I with its generic name in Section II.
______ 1. Byvalson (Allergan USA)
______ 2. Yosprala (Aralez Pharmaceuticals U.S.)
______ 3. Entresto (Novartis)
______ 4. Prestalia (Symplmed)
a. sacubitril and valsartan. These film-coated tablets combine an angiotensin II receptor blocker (ARB) and a neprilysin inhibitor. This drug is indicated to reduce the risk of cardiovascular death and hospitalization in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.
b. perindopril and amlodipine. Indicated to manage hypertension, this drug combines an angiotensin-converting enzyme inhibitor and a dihydropyridine calcium channel blocker. This drug isn't recommended for use in patients with severe renal impairment.
c. nebivolol and valsartan. This drug, indicated to treat hypertension, is a combination of a beta-1 selective beta-blocker and an ARB. It can be administered with or without food. Warn patients not to discontinue the drug abruptly. In general, patients with bronchospastic disorders should avoid beta-blockers.
d. aspirin and omeprazole. Combining an antiplatelet agent and a proton pump inhibitor, this drug is indicated to reduce the risk of aspirin-associated gastric ulcers in at-risk patients who need aspirin for secondary prevention of cardiovascular and cerebrovascular events. Teach patients to take each daily dose at least 1 hour before a meal, and warn them not to split, chew, crush, or dissolve the tablets.
Resources available upon request.
ANSWERS: 1c, 2d, 3a, 4b